Pilot Feasibility Core for MGNet (Myasthenia Gravis Network)
Official title: Pilot Feasibility Core
Funded at George Washington University · NIH-11414997 · Data updated 2026-11-12
A pilot program at MGNet helps researchers from many fields explore ideas that could lead to better tests, biomarkers, and treatments for myasthenia gravis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | September 1, 2019 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $76,018 |
| NIH project number | 5U54NS115054-07 |
| Project ID | NIH-11414997 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include MG researchers and clinicians who have ideas ready for pilot testing and access to MGNet resources or patient data.
✕Less likely to help
Patients not directly involved in the pilot or without MG-specific data or samples may not benefit from this grant.
What this research studies
This grant supports short, high-promise studies that could move MG research toward clinical trials, biomarker work, and new treatments. It connects with MGNet’s biobank and clinical data resources to enable investigators to test ideas using patient samples or related data. Researchers from basic science and clinical backgrounds can collaborate through a formal process that includes peer review and program meetings. The core aligns with patient advocacy groups to drive progress and share findings with the MG community.
Why it matters
Potential benefit: If successful, the program could speed up the discovery of MG biomarkers and pave the way for new therapies or trial-ready research.
How similar studies have gone: MGNet pilots have previously advanced investigator-led discovery and biomarker work through integrated data and samples.
Where this research is happening
-
George Washington University
Washington, United States Active
Researchers
- Principal investigator: Kusner, Linda Louise — George Washington University
- Study coordinator: Kusner, Linda Louise
Related research
Other NIH-funded projects on the same topics.
-
HLA-F and KIR3DS1: unlocking NK cell help to control HIV
A short, patient-friendly look at how a specific immune interaction might help the body control HIV and reduce long-term health problems.
-
Emerging therapies for rare maternal mitochondrial diseases with shared causes
A basket clinical trial will test new drug candidates for two ultra-rare mitochondrial diseases (MELAS and LHON-Plus) that share the same underlying energy-making problem in people who could be affected.
-
Anti-cancer vaccine for liver fluke infection and bile duct cancer
A vaccine approach aims to stop liver fluke interactions with the human bile ducts to prevent bile duct cancer in regions where the parasite is common.
-
Anti-cancer vaccine targeting the host-parasite interface during liver fluke infection
A vaccine approach aims to block how a liver fluke parasite communicates with the human liver to prevent bile duct cancer in people in Southeast Asia.
-
Understanding why youth develop type 2 diabetes and how to prevent it
A nationwide study aims to unravel why some teens with obesity develop type 2 diabetes while others don’t, and to identify factors that could help prevent it.
-
Ultrasensitive antibody-detection method to screen HIV-bNAbs
A new, ultra-sensitive test will help identify which broadly neutralizing antibodies can best block HIV-1 in people, by quickly checking how well these antibodies interact with the virus in patient-derived samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.